Contineum Therapeutics (CTNM) Baird Global Healthcare Conference 2025 summary

Company overview and clinical pipeline

• Focus on neuroscience, inflammation, and immunology with two clinical-stage assets and multiple near-term readouts expected.

• PIPE-791 is a first-in-class brain-penetrant LPA-1 receptor inhibitor advancing in IPF, with phase II proof-of-concept study initiation planned before year-end.

• PIPE-307, a selective M1 receptor inhibitor, is in phase II studies for remyelination in MS and MDD, in collaboration with J&J.

• Cash runway extends through 2027, supporting execution of key milestones.

PIPE-791: Mechanism, differentiation, and clinical strategy

• LPA-1 receptor antagonism in IPF is supported by strong preclinical and clinical validation, with prior BMS programs informing risk and differentiation.

• Unique pharmacokinetic profile enables QD dosing, extended receptor coverage, and potentially improved safety and efficacy compared to competitors.

• PET receptor occupancy studies validate dose selection, aiming for high target engagement and efficacy.

• Phase II IPF trial design ensures comparability with BMS studies for clear benchmarking.

• Exploratory pain study in osteoarthritis and chronic lower back pain uses a crossover design to identify signals for future development.

Pipeline prioritization and operational focus

• Initiation of progressive MS and CTX-343 programs postponed to prioritize global phase II IPF study; budgets remain allocated for future re-engagement.

• Operational focus is on successful execution of large, multi-site IPF trial before expanding pipeline activities.